Pharmaceutical revenue declined as one-off projects for new drug application materials fell back
First written in FY2020-Q1. 8 of 9 entries say "Mitigated", first in FY2020-Q2. Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022MitigatedAnnual report
「In the pharmaceutical sector, orders from foreign pharmaceutical companies remained strong and business with domestic pharmaceutical companies progressed steadily, resulting in revenue rising 1.0% year on year to ¥2,904 million.」
Against the risk of lower pharmaceutical-sector revenue following the reversal of one-off projects, strong orders from foreign pharmaceutical companies and steady business with domestic pharmaceutical companies resulted in full-year revenue growth. - FY2022-Q3MitigatedAnnual report
「In the pharmaceutical sector, orders from foreign pharmaceutical companies remained strong, and business with domestic pharmaceutical companies also progressed steadily. Revenue therefore rose 4.7% year on year to ¥2,175 million.」
Against the risk of lower pharmaceutical-sector revenue following the reversal of one-off projects in the same period of the previous year, orders from foreign pharmaceutical companies and business with domestic pharmaceutical companies remained firm, and revenue growth continued. - FY2022-Q2MitigatedAnnual report
「In the pharmaceutical sector, orders from foreign pharmaceutical companies remained strong, and business with domestic pharmaceutical companies also progressed steadily. As a result, revenue rose 7.9% year on year to ¥1,448 million.」
The risk of lower revenue following the reversal of one-off projects in the same period of the previous year has been offset by strong orders from foreign pharmaceutical companies and steady business with domestic pharmaceutical companies, with revenue growth continuing in the pharmaceutical sector. - FY2022-Q1MitigatedAnnual report
「In the pharmaceutical sector, which maintained revenue growth in the previous fiscal year, orders from foreign pharmaceutical companies remained strong and business with domestic pharmaceutical companies also expanded. Revenue therefore rose 8.5% year on year to ¥715 million.」
The risk of lower revenue following the reversal of one-off projects in the same period of the previous year has continued to give way to revenue growth in the pharmaceutical sector, supported by strong orders from foreign pharmaceutical companies and expanded business with domestic pharmaceutical companies. - FY2021MitigatedAnnual report
「In the pharmaceutical sector, orders from foreign pharmaceutical companies remained strong, and business with domestic pharmaceutical companies also remained steady. As a result, revenue rose 4.5% year on year to ¥2,875 million.」
Following the decline caused by the reversal of one-off projects in the same period of the previous year, full-year revenue increased in the pharmaceutical sector on the back of strong orders from foreign pharmaceutical companies and steady business with domestic pharmaceutical companies. - FY2021-Q2MitigatedAnnual report
「In the pharmaceutical sector, stable orders from foreign pharmaceutical companies, together with steady business with domestic pharmaceutical companies, resulted in revenue rising 2.0% year on year to ¥1,341 million.」
The risk of lower pharmaceutical-sector revenue following the reversal of one-off projects in the same period of the previous year had turned into cumulative revenue growth for the quarter, supported by stable orders from foreign pharmaceutical companies and steady business with domestic pharmaceutical companies. - FY2021-Q1MitigatedAnnual report
「In the pharmaceutical sector, orders from foreign pharmaceutical companies remained strong, and business with domestic pharmaceutical companies also expanded. As a result, revenue rose 10.7% year on year to ¥659 million.」
Rather than a decline following one-off projects for new drug application materials and other items in the same period of the previous year, the pharmaceutical sector reported higher revenue due to strong orders from foreign pharmaceutical companies and expanded business with domestic pharmaceutical companies. - FY2020-Q2MitigatedAnnual report
「In the pharmaceutical sector, orders from major customers, including pharmaceutical companies, remained firm, but could not fully offset the decline following the large projects recorded in the same period of the previous year. Revenue fell 4.4% year on year to ¥1,314 million.」
The decline following the large projects recorded in the same period of the previous year continued, but the extent of the decline narrowed to 4.4% from the 18.2% decline in the previous quarter, and orders from major customers were described as firm. - FY2020-Q1First statedAnnual report
「In the pharmaceutical sector, the company won large projects from several pharmaceutical companies and others, but revenue also declined following the reversal of one-off projects for new drug application materials recorded in the same period of the previous year. Revenue fell 18.2% year on year to ¥595 million.」
The expected decline following the one-off projects for new drug application materials in the same period of the previous year materialized, and the pharmaceutical sector reported lower revenue despite winning several large projects.